On November 19, 2024, our CEO, Aristóbulo Loaiza, proudly represented HEDROS at the prestigious Phage Futures 2024 event in Boston, a leading platform for advancing phage therapy solutions across industries. HEDROS discussed the need to tailor phage solution development according to the regional microbiome control needs.
The theme for Phage Futures 2024 was Accelerating the translation of bacteriophages from bench to clinically & commercially viable products. Phage Futures 2024 brought together experts from around the globe to address critical challenges in regulation, manufacturing, investment, and R&D of bacteriophage-based technologies. Discussions highlighted the growing threat of antimicrobial resistance (AMR) and the importance of phage therapies in aquaculture, human health, animal health, and nutrition.
Aristóbulo Loaiza highlighted HEDROS’s ongoing commitment to combating vibriosis in shrimp farming, an issue critical to the sustainability and health of the aquaculture industry. Our research and development efforts are focused on delivering innovative bacteriophage-based solutions that address these challenges effectively.
Phage Futures 2024 reaffirmed our belief that bacteriophages are not only critical to the future of sustainable, safe food production but also hold immense potential across diverse industries. At HEDROS, we are proud to be part of this global movement.
We extend our gratitude to the organizers of Phage Futures 2024 and the participants. In 2025, we look forward to continuing our collaborations with global animal health manufacturers, regional food-animal producers and regulators to advance the application of phage technologies.
Comments